News on China's scientific and technological development.

tokenanalyst

Brigadier
Registered Member

Investing 150 million yuan! High-end CNC Equipment Production officially started.​


the total investment of the Top Aerospace High-end CNC Equipment Production, R&D and Operation Headquarters Project is about 150 million yuan, with a construction area of 37,150 square meters. The project is mainly committed to achieving independent control and comprehensive localization of the industrial mother machine industry chain, playing a key role in assisting the mass production of domestic large aircraft, the development of manned spacecraft, and the large-scale delivery of new energy vehicles. It will escort the technical security of key areas such as my country's aerospace, and play an important role in strengthening and supplementing the chain in building an industrial ecology and expanding and strengthening the intelligent manufacturing equipment industry chain.

Shanghai Technology Co., Ltd. is a high-end five-axis machine tool manufacturer. Since its establishment in 2007, it has always focused on the core technology of China's high-end CNC equipment, insisted on product intelligence and high-end technology as the focus of corporate development, and has grown into a well-known high-end intelligent manufacturing equipment supplier in the aerospace field. The company has developed many highlight products and stood at the forefront of the international aerospace field, especially in the five-axis machining center, double five-axis mirror milling system, rocket body and aircraft fuselage automation department assembly equipment and other aspects to fill a number of domestic gaps. It has developed the world's first three-head parallel mirror milling equipment, the world's first vertical box bottom mirror milling, and the world's largest 12-meter-class horizontal double five-axis skin mirror milling. Topu CNC has also provided a large number of key core equipment for my country's C919/C929 commercial aircraft, commercial aerospace, new energy vehicles, etc.

 

canonicalsadhu

Junior Member
Registered Member
Please, Log in or Register to view URLs content!
China’s R&D investment intensity (the ratio of R&D expenditure to GDP) reached 2.68 percent, a 0.10 percentage point rise from the previous year.
China’s R&D investment intensity ranks 12th among the major countries worldwide, surpassing the average level of 2.11 percent in EU countries, and further approaching the average level of 2.73 percent for OECD countries.
China’s expenditure on basic research totaled 249.7 billion yuan, growing 10.5 percent year-on-year.
Given China's GDP/capita, China's R&D intensity is remarkably high and rising fast, will possibly overtake rich-club OECD's average next year.
 

antwerpery

Junior Member
Registered Member
Please, Log in or Register to view URLs content!
YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating transfusion-dependent beta-thalassemia (TDT).TDT is a genetic blood disorder characterised by beta-globin gene mutations, resulting in a decrease or absence of haemoglobin. Affected patients need blood transfusions regularly for anaemia management to avoid complications in the future.

The dose-escalation trial is designed to assess the efficacy and safety of a single-dose regimen with the therapy, which may offer an off-the-shelf treatment for individuals with this condition. This can potentially eliminate the need for conditioning chemotherapy and haematopoietic stem cell transplantation (HSCT), on the success of the trial.

YolTech Therapeutics CEO and founder Dr Yuxuan Wu said: “The initiation of the clinical trial for YOLT-204 represents a significant milestone of gene editing therapy development for TDT and SCD [Stearoyl-CoA Desaturase]. We are excited to collaborate with our clinical investigators to bring this innovative therapy to patients.”YOLT-204 utilises the company’s lipid nanoparticles (LNP) and edits the haemoglobin regulatory area for inducing foetal haemoglobin expression.

With this process, it may be possible to correct the haemoglobin imbalance and red blood cell deficiency in individuals with TDT. Pre-clinical models suggest that the therapy has exhibited ‘sustained’ and ‘effective’ foetal haemoglobin induction.
 

Wrought

Senior Member
Registered Member
A nice visualization of overlapping synergies between companies+tech. Obviously not comprehensive, but good for illustrative purposes.
https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd2dde1c1-daf6-4efa-a470-11bd6c2e75df_3002x2107.png


From this blog:
Please, Log in or Register to view URLs content!
 

mossen

Junior Member
Registered Member
now we're witnessing its technological Sputnik moment.
To me that was during Trump's first term when the US failed to kill Huawei. That's when I knew it was game over. What we're seeing now is far less dramatic.

Also, I'm not sure if Sputnik is the right analogy. Ultimately the US won the space race. I doubt it will win the technological contest with China. The moats keep disappearing for America, one after another.
 
Top